Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 2012-2020

  Santos, Alexandre ^a   Zanetta, Sylvie ^b   Cresteil, Thierry ^a   Deroussent, Alain ^a   Pein, François ^a   Raymond, Eric ^a   Vernillet, Laurent ^c,d   Risse, Marie Laure ^c,d   Boige, Valerie ^a   Gouyette, Alain ^a   Vassal, Gilles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE LÉON BÉRARD   (France)

^c SANOFI   (France)

^d Bellon   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DNA TOPOISOMERASE INHIBITOR; DRUG METABOLITE; IRINOTECAN;

ADOLESCENT; AGED; ARTICLE; BIOTRANSFORMATION; CASE REPORT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOLECULAR WEIGHT; OXIDATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADOLESCENT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; NEOPLASMS;

EID: 17444443721     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Vassal, G., Boland, I., Santos, A., Bissery, M. C., Terrier-Lacombe, M. J., Morizet, J., Sainte-Rose, C., Lellouch, T., Kalifa, C., and Gouyette, A. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int. J. Cancer, 73: 156-163, 1997.
2. Vassal, G., Terrier-Lacombe, M. J., Bissery. M. C., Vénuat, A. M., Gyergyay, F., Bénard, J., Morizet, J., Boland, I., Ardouin, P., Bressac-de-Paillerets, B., and Gouyette, A. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumor and neuroblastoma xenografts. Br. J. Cancer, 74: 537-545, 1996.
3. Vassal, G., Pondarré, C., Cappelli, C., Terrier-Lacombe, M. J., Boland, I., Morizet, J., Bénard, J., Vénuat, A. M., Ardouin, P., Hartmann, O., and Gouyette, A. DNA-topoisomerase I, a new target for the treatment of neuroblastoma. Eur. J. Cancer. 33: 2011-2015, 1997.
4. Thompson, J., Zamboni, W. C., Cheshire, P. J., Richmond, L., Luo, X., Houghton, J. A., Stewart, C. F., and Houghton, P. J. Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs. 8: 313-322, 1997.
5. Cottu, P. H., Extra, J. M., Lerebours, F., Espié, M., and Marty, M. Clinical activity of irinotecan. Bull. Cancer, Dec., 21-25, 1998.
6. Shimada, Y., Rougier, P., and Pilot, H. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur. J. Cancer. 32A (Suppl. 3): S13-S17, 1996.
7. Hsiang, Y. H., Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Kirscheubaum, S., Silber, R., and Potmesil, M. DNA topoisomerase I- mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res., 49: 4385-4389, 1989.
8. Jaxel, C., Kohn, K. W., Wani. M. C., Wall, M. E., and Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res., 49: 1465-1469, 1989.
9. Chen, A. Y., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Ann. Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
10. Creemers, G. J., Lund, B., and Verweij, J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat. Rev., 20: 73-96, 1994.
11. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38. a metabolite of camptothecin derivative CPT-11 in the antitumor effect of CPT-11. Cancer Res., 51: 4187-4191, 1991.
12. Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., and Ratain, M. J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest., 15: 847-854, 1998.
13. Kaneda, N., Nagata, H., Furuta, T., and Yokokura, T. Metabolism and pharmacokinetics of camptothecin analogue CPT-11 in the mouse. Cancer Res., 50: 1715-1720, 1990.
14. Haaz, M. C., Rivory, L., Riché, C., Vernillet, L., and Robert, J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res., 58: 468-472, 1998.
15. Dodds, H. M., Haaz, M. C., Riou, J. F., Robert, J., and Rivory, L. P. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J. Pharmacol. Exp. Ther., 286: 578-583, 1998.
16. Lokiec, F., Monegier du Sorbier, B., and Sanderink, G. J. Irinotecan (CPT-11) metabolites in human bile and urine. Clin. Cancer Res., 2: 1943-1949, 1996.
17. Rivory, L., Riou, J. F., Haaz, M. C., Sable, S., Vuilhorgne, M., Commerçon, A., Pond, S. M., and Robert, J. Identification and properties of major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res., 56; 3689-3694, 1996.
18. Lacroix, D., Sonnier, M., Moncion, A., Cheron, G., and Cresteil, T. Expression of CYP 3A in the human liver. Evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur. J. Biochem., 247: 625-634, 1997.
19. Sonnier, M., and Cresteil, T. Delayed ontogenesis of CYP1A2 in the human liver. Eur. J. Biochem., 251: 893-898, 1998.
20. Cresteil, T., Beaune, P., Kremers, P., Celier, C., Guengerich, P., and Leroux, J. P. Immunoquantification of epoxide hydrolase and cytochrome P-450 isoenzymes in fetal and adult human liver microsomes. Eur. J. Biochem., 151: 345-350, 1985.
21. Wrighton. S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, P., Raucy, J. L., Malowa, D. T., and Vandenbranden, M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol., 38: 207-213, 1990.
22. Shou, M., Martinet, M., Korzekwa, K. R., Krausz, K. W., Gonzalez, F. J., and Gelboin, H. V. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics, 8: 391-401, 1998.
23. Gupta, E., Wang, X., Ramirez, J., and Ratain, M. J. Modulation of glucuronidation of SN-38. the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother. Pharmacol., 39: 440-444, 1997.
24. Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., Cloughsey, T., Stewart, E. S., Colvin, O. M., Provenzale, J. M., Mclendon, R. E., Bigner, D. D., Cokgor, I., Haglund, M., Rich, J., Ashley, D., Malczyn, J., Elfring, G. L., and Miller, L. L. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol., 17: 1515-1525, 1999.